{"id":"atosiban","rwe":[],"tags":[{"label":"atosiban","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Vasopressin V1a receptor","category":"target"},{"label":"AVPR1A","category":"gene"},{"label":"OXTR","category":"gene"},{"label":"AVPR1B","category":"gene"},{"label":"G02CX01","category":"atc"},{"label":"Active","category":"status"},{"label":"Prevention of Premature Labor","category":"indication"},{"label":"Ferring Pharmaceuticals A/S","category":"company"},{"label":"Hormone Antagonists","category":"pharmacology"},{"label":"Reproductive Control Agents","category":"pharmacology"},{"label":"Tocolytic Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":1021.465,"date":"","count":229,"signal":"Premature baby","source":"DrugCentral FAERS","actionTaken":"Reported 229 times (LLR=1021)"},{"llr":755.937,"date":"","count":159,"signal":"Premature delivery","source":"DrugCentral FAERS","actionTaken":"Reported 159 times (LLR=756)"},{"llr":646.504,"date":"","count":79,"signal":"Normal labour","source":"DrugCentral FAERS","actionTaken":"Reported 79 times (LLR=647)"},{"llr":641.09,"date":"","count":212,"signal":"Maternal exposure during pregnancy","source":"DrugCentral FAERS","actionTaken":"Reported 212 times (LLR=641)"},{"llr":556.484,"date":"","count":78,"signal":"Delivery","source":"DrugCentral FAERS","actionTaken":"Reported 78 times (LLR=556)"},{"llr":300.578,"date":"","count":101,"signal":"Foetal exposure during pregnancy","source":"DrugCentral FAERS","actionTaken":"Reported 101 times (LLR=301)"},{"llr":244.401,"date":"","count":116,"signal":"Product use in unapproved indication","source":"DrugCentral FAERS","actionTaken":"Reported 116 times (LLR=244)"},{"llr":197.14,"date":"","count":50,"signal":"Low birth weight baby","source":"DrugCentral FAERS","actionTaken":"Reported 50 times (LLR=197)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"company":"Ferring Pharmaceuticals A/S","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ATOSIBAN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:16:34.432934+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:16:40.145573+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:16:34.504778+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ATOSIBAN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:16:40.443436+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Oxytocin receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:16:41.508661+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL382301/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:16:41.155659+00:00"}},"allNames":"antocin ii","offLabel":[],"synonyms":["atosiban acetate","atosiban","Antocin II","antocin","tractocil","tractocile"],"timeline":[{"date":"2000-01-20","type":"positive","source":"DrugCentral","milestone":"EMA approval (Ferring Pharmaceuticals A/S)"}],"brandName":"Antocin Ii","ecosystem":[{"indication":"Prevention of Premature Labor","otherDrugs":[{"name":"hydroxyprogesterone caproate","slug":"hydroxyprogesterone-caproate","company":"Actavis Labs Ut Inc"},{"name":"progesterone","slug":"progesterone","company":"Alza"}],"globalPrevalence":null}],"mechanism":{"target":"Vasopressin V1a receptor","targets":[{"gene":"AVPR1A","source":"DrugCentral","target":"Vasopressin V1a receptor","protein":"Vasopressin V1a receptor"},{"gene":"OXTR","source":"DrugCentral","target":"Oxytocin receptor","protein":"Oxytocin receptor"},{"gene":"AVPR1B","source":"DrugCentral","target":"Vasopressin V1b receptor","protein":"Vasopressin V1b receptor"},{"gene":"AVPR2","source":"DrugCentral","target":"Vasopressin V2 receptor","protein":"Vasopressin V2 receptor"}],"modality":"Small Molecule","drugClass":"atosiban","explanation":"","oneSentence":"","technicalDetail":"Atosiban is a selective antagonist of the vasopressin V1a receptor, which is involved in the regulation of uterine contractions. By blocking the V1a receptor, atosiban reduces the contractility of the uterus, thereby preventing premature labor."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3008","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ATOSIBAN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ATOSIBAN","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T08:46:59.860932","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:16:42.847111+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"flibanserin","drugSlug":"flibanserin","fdaApproval":"2015-08-18","patentExpiry":"May 9, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"bremelanotide","drugSlug":"bremelanotide","fdaApproval":"2019-06-21","patentExpiry":"Nov 5, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"fezolinetant","drugSlug":"fezolinetant","fdaApproval":"2023-05-12","patentExpiry":"Mar 28, 2034","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"atosiban","indications":{"approved":[{"name":"Prevention of Premature Labor","source":"DrugCentral","snomedId":"","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"flibanserin","brandName":"flibanserin","genericName":"flibanserin","approvalYear":"2015","relationship":"same-class"},{"drugId":"bremelanotide","brandName":"bremelanotide","genericName":"bremelanotide","approvalYear":"2019","relationship":"same-class"},{"drugId":"fezolinetant","brandName":"fezolinetant","genericName":"fezolinetant","approvalYear":"2023","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07185230","phase":"NA","title":"Atosiban in Women With Previous Implantation Failure and Abnormal Uterine Contractions","status":"RECRUITING","sponsor":"Northwest Women's and Children's Hospital, Xi'an, Shaanxi","startDate":"2025-12-06","conditions":["Infertility"],"enrollment":792,"completionDate":"2027-09-30"},{"nctId":"NCT07140237","phase":"EARLY_PHASE1","title":"The Effect of Oral Oxytocin and Atosiban on Top-down Attention ( OTAtosiban )","status":"RECRUITING","sponsor":"University of Electronic Science and Technology of China","startDate":"2025-09","conditions":["Healthy Adult Male"],"enrollment":250,"completionDate":"2025-12-30"},{"nctId":"NCT07093060","phase":"EARLY_PHASE1","title":"The Effect of Oral Oxytocin and Atosiban on Social Attention","status":"RECRUITING","sponsor":"University of Electronic Science and Technology of China","startDate":"2025-06-09","conditions":["Healhty"],"enrollment":250,"completionDate":"2025-11-30"},{"nctId":"NCT06537778","phase":"NA","title":"Perioperative Use of Atosiban for Ultrasound-indicated Cerclage to Reduce Spontaneous Preterm Birth(sPTB)","status":"COMPLETED","sponsor":"Children's Hospital of Chongqing Medical University","startDate":"2018-01-03","conditions":["Cervical Cerclage","Premature Birth"],"enrollment":334,"completionDate":"2024-04-12"},{"nctId":"NCT05693688","phase":"PHASE4","title":"Atosiban Versus Placebo in the Treatment of Late Threatened Pre-term Birth","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2017-12-01","conditions":["Preterm Birth"],"enrollment":760,"completionDate":"2024-02-29"},{"nctId":"NCT04468568","phase":"","title":"In Utero Repair of Myelomeningocele: Atosiban Versus Terbutaline","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2017-10-01","conditions":["Myelomeningocele","Terbutaline Adverse Reaction","Pregnancy; Malformation Central Nervous System"],"enrollment":25,"completionDate":"2022-04-01"},{"nctId":"NCT05382143","phase":"PHASE2","title":"The Effect of Selective Oxytocin Receptor Inhibitors on Endometriosis-related Pain","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2022-02-01","conditions":["Endometriosis"],"enrollment":10,"completionDate":"2022-07-01"},{"nctId":"NCT04118959","phase":"","title":"Role of Atosiban in Recurrent Implantation Failure","status":"UNKNOWN","sponsor":"Al Baraka Fertility Hospital","startDate":"2019-10-10","conditions":["Recurrent Implantation Failure"],"enrollment":150,"completionDate":"2021-11-25"},{"nctId":"NCT03369262","phase":"PHASE2","title":"PoC Study of OBE022 in Threatened Preterm Labour","status":"UNKNOWN","sponsor":"ObsEva SA","startDate":"2018-01-10","conditions":["Preterm Labor"],"enrollment":115,"completionDate":"2022-08"},{"nctId":"NCT01673399","phase":"PHASE4","title":"Oxytocin Antagonist in Patients With Repeated Failure of Implantation","status":"COMPLETED","sponsor":"AZ Jan Palfijn Gent","startDate":"2012-02","conditions":["Implantation Failure"],"enrollment":138,"completionDate":"2015-02"},{"nctId":"NCT03904745","phase":"NA","title":"Effect of Oxytocin Antagonists on Implantation Success Rates of Frozen-thawed Embryo Transfer","status":"UNKNOWN","sponsor":"Bezmialem Vakif University","startDate":"2020-12-21","conditions":["Infertility, Female"],"enrollment":250,"completionDate":"2021-12-30"},{"nctId":"NCT02292771","phase":"PHASE3","title":"A Randomized Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban for Women in Spontaneous Preterm Labour","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2015-03-16","conditions":["Obstetric Labour, Premature"],"enrollment":97,"completionDate":"2017-08-25"},{"nctId":"NCT02292784","phase":"PHASE3","title":"Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-06-01","conditions":["Obstetric Labour, Premature"],"enrollment":98,"completionDate":"2019-09-02"},{"nctId":"NCT03570294","phase":"NA","title":"Oxidative Stress in Women Treated With Atosiban for Impending Preterm Birth","status":"COMPLETED","sponsor":"Polish Mother Memorial Hospital Research Institute","startDate":"2014-02-01","conditions":["Premature Birth"],"enrollment":64,"completionDate":"2018-12-30"},{"nctId":"NCT00587327","phase":"PHASE2","title":"Effect of Oxytocin and Vasopressin Antagonists on Uterine Contractions","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2007-11","conditions":["In Vitro Fertilisation (IVF) Treatment"],"enrollment":125,"completionDate":"2008-09"},{"nctId":"NCT02893722","phase":"PHASE1","title":"A Randomized Double Blind Comparison of Atosiban in Patients With RIF Undergoing IVF Treatment","status":"UNKNOWN","sponsor":"Shanghai First Maternity and Infant Hospital","startDate":"2017-01","conditions":["Repeated Implantation Failure"],"enrollment":200,"completionDate":"2018-12"},{"nctId":"NCT02725736","phase":"PHASE3","title":"Tocolytic Therapy for Preterm Labor in Multiple Gestation","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2016-03","conditions":["Labor Preterm Multiple"],"enrollment":140,"completionDate":"2018-03"},{"nctId":"NCT01314859","phase":"PHASE3","title":"Nifedipine Treatment in Preterm Labor","status":"WITHDRAWN","sponsor":"Hospital Clinico Universitario de Santiago","startDate":"2011-07","conditions":["Threatened Preterm Labor"],"enrollment":0,"completionDate":"2013-07"},{"nctId":"NCT01501214","phase":"PHASE4","title":"Use of Atosiban in in Vitro Fertilization (IVF) Treatment","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2011-12","conditions":["Subfertility"],"enrollment":800,"completionDate":"2013-12"},{"nctId":"NCT00599898","phase":"PHASE4","title":"Nifedipine Compared to Atosiban for Treating Preterm Labor","status":"COMPLETED","sponsor":"Raed Salim","startDate":"2008-01","conditions":["Labor, Premature"],"enrollment":145,"completionDate":"2012-02"},{"nctId":"NCT01493440","phase":"NA","title":"Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure","status":"COMPLETED","sponsor":"An Sinh Hospital","startDate":"2011-03","conditions":["Repeated Implantation Failure"],"enrollment":71,"completionDate":"2011-09"},{"nctId":"NCT01429545","phase":"PHASE2","title":"Single Versus Combination Therapy in Acute Tocolysis","status":"COMPLETED","sponsor":"Tawam Hospital","startDate":"2007-04","conditions":["Preterm Labour"],"enrollment":110,"completionDate":"2011-03"},{"nctId":"NCT00679705","phase":"PHASE1","title":"Influence of Tocolytical Medications on Hemodynamics (Central and Peripheral) and Vascular Function in a Pilot Study to Determine the Design of the Final Study and the Final Study Itself","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2008-05","conditions":["Healthy"],"enrollment":23,"completionDate":"2008-11"}],"_emaApprovals":[{"date":"2000-01-20","status":"Authorised","company":"Ferring Pharmaceuticals A/S"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"008327","UNII":"081D12SI0Z","CHEBI":"CHEBI:135899","INN_ID":"6392","RXNORM":"59639","UMLSCUI":"C0164398","chemblId":"CHEMBL382301","ChEMBL_ID":"CHEMBL382301","KEGG_DRUG":"D03008","DRUGBANK_ID":"DB09059","PUBCHEM_CID":"5311010","SNOMEDCT_US":"326166008","IUPHAR_LIGAND_ID":"2213","SECONDARY_CAS_RN":"914453-95-5","MESH_SUPPLEMENTAL_RECORD_UI":"C047046"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Ferring Pharmaceuticals A/S","relationship":"Current Owner"}],"publicationCount":560,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"G02CX01","allCodes":["G02CX01"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Ferring Pharmaceuticals A/S","companyId":"ferring-pharmaceuticals-a-s","modality":"Recombinant protein","firstApprovalDate":"2000","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:16:42.847111+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}